While Integra Lifesciences Holdings Corp has overperformed by 2.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IART fell by -55.35%, with highs and lows ranging from $45.42 to $16.96, whereas the simple moving average fell by -46.26% in the last 200 days.
On July 30, 2024, Citigroup Downgraded Integra Lifesciences Holdings Corp (NASDAQ: IART) to Sell. A report published by BTIG Research on July 30, 2024, Downgraded its rating to ‘Sell’ for IART. Wells Fargo also Downgraded IART shares as ‘Equal Weight’, setting a target price of $25 on the company’s shares in a report dated May 07, 2024. Citigroup April 03, 2024d its ‘Sell’ rating to ‘Neutral’ for IART, as published in its report on April 03, 2024. Wells Fargo’s report from December 05, 2023 suggests a price prediction of $49 for IART shares, giving the stock a ‘Overweight’ rating. CL King also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Integra Lifesciences Holdings Corp (IART)
Further, the quarter-over-quarter increase in sales is 9.68%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Integra Lifesciences Holdings Corp’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 1.47% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.52M can be a very valuable indicator of volatility for IART stock. On a monthly basis, the volatility of the stock is set at 3.86%, whereas on a weekly basis, it is put at 4.61%, with a loss of -0.40% over the past seven days. Furthermore, long-term investors anticipate a median target price of $27.70, showing growth from the present price of $17.53, which can serve as yet another indication of whether IART is worth investing in or should be passed over.
How Do You Analyze Integra Lifesciences Holdings Corp Shares?
The USA based company Integra Lifesciences Holdings Corp (IART) is one of the biggest names in Medical Devices. When comparing Integra Lifesciences Holdings Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 59.40, there is a growth in quarterly earnings of -410.47%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.14%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.63% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IART shares are owned by institutional investors to the tune of 90.63% at present.
